Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cv Therapeutics Inc (CVTX) since 2006 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Cv Therapeutics Inc. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 921506.
Total stock buying since 2006: $0.
Total stock sales since 2006: $14,026,759.
Total stock option exercises since 2006: $25,196,819.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2009 | 0 | $0 | 623,204 | $12,380,789 | 1,643,408 | $22,982,635 |
| 2008 | 0 | $0 | 73,242 | $669,922 | 190,620 | $1,328,515 |
| 2007 | 0 | $0 | 70,967 | $716,568 | 189,642 | $519,919 |
| 2006 | 0 | $0 | 12,800 | $259,480 | 113,235 | $365,750 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2009-04 | 0 | $0 | 620,204 | $12,343,469 | 1,543,765 | $21,386,422 |
| 2009-03 | 0 | $0 | 0 | $0 | 11,345 | $225,538 |
| 2009-02 | 0 | $0 | 1,500 | $23,250 | 87,497 | $1,363,202 |
| 2009-01 | 0 | $0 | 1,500 | $14,070 | 801 | $7,473 |
| 2008-12 | 0 | $0 | 1,002 | $9,248 | 70,746 | $635,395 |
| 2008-11 | 0 | $0 | 4,000 | $37,359 | 0 | $0 |
| 2008-10 | 0 | $0 | 2,000 | $17,860 | 0 | $0 |
| 2008-09 | 0 | $0 | 1,289 | $14,823 | 11,345 | $0 |
| 2008-08 | 0 | $0 | 5,500 | $56,055 | 0 | $0 |
| 2008-07 | 0 | $0 | 13,766 | $128,384 | 12,500 | $72,625 |
| 2008-06 | 0 | $0 | 839 | $6,653 | 11,346 | $0 |
| 2008-04 | 0 | $0 | 15,388 | $145,213 | 12,500 | $72,625 |
| 2008-03 | 0 | $0 | 3,213 | $23,519 | 11,345 | $0 |
| 2008-02 | 0 | $0 | 0 | $0 | 50,001 | $455,370 |
| 2008-01 | 0 | $0 | 26,245 | $230,808 | 10,837 | $92,500 |
| 2007-12 | 0 | $0 | 51,470 | $492,714 | 33,845 | $169,919 |
| 2007-11 | 0 | $0 | 2,497 | $25,444 | 0 | $0 |
| 2007-09 | 0 | $0 | 0 | $0 | 11,346 | $0 |
| 2007-08 | 0 | $0 | 10,000 | $100,900 | 10,000 | $90,000 |
| 2007-06 | 0 | $0 | 0 | $0 | 11,345 | $0 |
| 2007-03 | 0 | $0 | 0 | $0 | 36,345 | $222,500 |
| 2007-02 | 0 | $0 | 0 | $0 | 5,292 | $37,500 |
| 2007-01 | 0 | $0 | 7,000 | $97,510 | 81,469 | $0 |
| 2006-12 | 0 | $0 | 4,800 | $63,240 | 52,169 | $0 |
| 2006-08 | 0 | $0 | 0 | $0 | 26,800 | $235,750 |
| 2006-05 | 0 | $0 | 0 | $0 | 25,500 | $110,000 |
| 2006-03 | 0 | $0 | 8,000 | $196,240 | 8,000 | $20,000 |
| 2006-01 | 0 | $0 | 0 | $0 | 766 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-04-08 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Option Ex | 117,058 | 12.39 | 1,449,880 |
| 2009-04-07 | Shenk Thomas E (Director) | Option Ex | 35,000 | 13.68 | 478,625 |
| 2009-04-07 | Gutshall Thomas L (Director) | Option Ex | 50,000 | 14.11 | 705,300 |
| 2009-04-06 | Costa Santo J (Director) | Option Ex | 50,000 | 14.11 | 705,300 |
| 2009-04-03 | Lee Kenneth B Jr (Director) | Option Ex | 56,250 | 14.11 | 793,462 |
| 2009-04-02 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Option Ex | 163,958 | 12.31 | 2,018,814 |
| 2009-04-02 | Spiegelman Daniel K (SVP, CFO) | Sale | 141,029 | 19.91 | 2,807,887 |
| 2009-04-02 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 188,958 | 12.31 | 2,326,639 |
| 2009-04-02 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 213,958 | 13.49 | 2,886,721 |
| 2009-04-02 | Lange Louis G (Chairman & CEO) | Sale | 479,175 | 19.90 | 9,535,582 |
| 2009-04-02 | Lange Louis G (Chairman & CEO) | Option Ex | 641,083 | 15.13 | 9,702,791 |
| 2009-04-02 | Davie Joseph Md Phd (Director) | Option Ex | 27,500 | 11.60 | 318,890 |
| 2009-03-25 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | 19.88 | 225,538 |
| 2009-02-25 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Option Ex | 12,499 | 15.58 | 194,734 |
| 2009-02-25 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 12,499 | 15.58 | 194,734 |
| 2009-02-25 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 12,499 | 15.58 | 194,734 |
| 2009-02-25 | Lange Louis G (Chairman & CEO) | Option Ex | 50,000 | 15.58 | 779,000 |
| 2009-02-06 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 1,500 | 15.50 | 23,250 |
| 2009-01-15 | Lange Louis G (Chairman & CEO) | Option Ex | 801 | 9.33 | 7,473 |
| 2009-01-07 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 1,500 | 9.38 | 14,070 |
| 2008-12-22 | Lange Louis G (Chairman & CEO) | Option Ex | 11,346 | 8.91 | 101,092 |
| 2008-12-11 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Option Ex | 2,700 | 8.48 | 22,896 |
| 2008-12-11 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Option Ex | 5,000 | 8.48 | 42,400 |
| 2008-12-11 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 5,000 | 8.48 | 42,400 |
| 2008-12-11 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 5,000 | 8.48 | 42,400 |
| 2008-12-11 | Lange Louis G (Chairman & CEO) | Option Ex | 12,000 | 8.48 | 101,760 |
| 2008-12-10 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Sale | 1,002 | 9.23 | 9,248 |
| 2008-12-09 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Option Ex | 2,700 | 9.51 | 25,677 |
| 2008-12-09 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Option Ex | 5,000 | 9.51 | 47,550 |
| 2008-12-09 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 5,000 | 9.51 | 47,550 |
| 2008-12-09 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 5,000 | 9.51 | 47,550 |
| 2008-12-09 | Lange Louis G (Chairman & CEO) | Option Ex | 12,000 | 9.51 | 114,120 |
| 2008-11-20 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Sale | 2,000 | 8.19 | 16,379 |
| 2008-11-06 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 2,000 | 10.49 | 20,980 |
| 2008-10-14 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 2,000 | 8.93 | 17,860 |
| 2008-09-22 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | .00 | 0 |
| 2008-09-09 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 1,289 | 11.50 | 14,823 |
| 2008-08-13 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 1,500 | 10.17 | 15,255 |
| 2008-08-08 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Sale | 4,000 | 10.20 | 40,800 |
| 2008-07-31 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 12,500 | 9.50 | 118,750 |
| 2008-07-31 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 12,500 | 5.81 | 72,625 |
| 2008-07-08 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 1,266 | 7.61 | 9,634 |
| 2008-06-23 | Lange Louis G (Chairman & CEO) | Option Ex | 11,346 | .00 | 0 |
| 2008-06-17 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 839 | 7.93 | 6,653 |
| 2008-04-30 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Sale | 2,888 | 9.12 | 26,338 |
| 2008-04-25 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 12,500 | 9.51 | 118,875 |
| 2008-04-25 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 12,500 | 5.81 | 72,625 |
| 2008-03-31 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Sale | 3,213 | 7.32 | 23,519 |
| 2008-03-24 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | .00 | 0 |
| 2008-02-26 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Option Ex | 4,688 | 6.95 | 32,581 |
| 2008-02-26 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Option Ex | 4,688 | 6.95 | 32,581 |
| 2008-02-26 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 4,688 | 6.95 | 32,581 |
| 2008-02-26 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 4,688 | 6.95 | 32,581 |
| 2008-02-26 | Lange Louis G (Chairman & CEO) | Option Ex | 18,750 | 6.95 | 130,312 |
| 2008-02-25 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Option Ex | 12,499 | 15.58 | 194,734 |
| 2008-01-31 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Sale | 16,245 | 8.36 | 135,808 |
| 2008-01-10 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 10,000 | 9.50 | 95,000 |
| 2008-01-10 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 10,000 | 9.25 | 92,500 |
| 2008-01-10 | Lange Louis G (Chairman & CEO) | Option Ex | 837 | .00 | 0 |
| 2007-12-24 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | .00 | 0 |
| 2007-12-21 | Spiegelman Daniel K (SVP, CFO) | Sale | 6,000 | 10.00 | 60,000 |
| 2007-12-19 | Suvari Tricia Borga (SVP, General Counsel & Sec) | Sale | 11,019 | 9.20 | 101,374 |
| 2007-12-18 | Gutshall Thomas L (Director) | Sale | 7,500 | 9.01 | 67,560 |
| 2007-12-18 | Gutshall Thomas L (Director) | Option Ex | 7,500 | 4.16 | 31,169 |
| 2007-12-11 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 18,951 | 9.69 | 183,540 |
| 2007-12-11 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 15,000 | 9.25 | 138,750 |
| 2007-12-10 | Spiegelman Daniel K (SVP, CFO) | Sale | 8,000 | 10.03 | 80,240 |
| 2007-11-09 | Stuart Lewis J (SVP COMMERCIAL OPERATIONS) | Sale | 2,497 | 10.19 | 25,444 |
| 2007-09-24 | Lange Louis G (Chairman & CEO) | Option Ex | 11,346 | .00 | 0 |
| 2007-08-16 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Sale | 10,000 | 10.09 | 100,900 |
| 2007-08-16 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 10,000 | 9.00 | 90,000 |
| 2007-06-22 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | .00 | 0 |
| 2007-03-30 | Mcneil Barbara J (Director) | Option Ex | 5,000 | 7.50 | 37,500 |
| 2007-03-22 | Lange Louis G (Chairman & CEO) | Option Ex | 11,345 | .00 | 0 |
| 2007-03-08 | Lange Louis G (Chairman & CEO) | Option Ex | 20,000 | 9.25 | 185,000 |
| 2007-02-22 | Lange Louis G (Chairman & CEO) | Option Ex | 292 | .00 | 0 |
| 2007-02-21 | Gutshall Thomas L (Director) | Option Ex | 5,000 | 7.50 | 37,500 |
| 2007-01-17 | Spiegelman Daniel K (SVP, CFO) | Sale | 7,000 | 13.93 | 97,510 |
| 2007-01-03 | Mccaleb David C (SVP Commercial Operations) | Option Ex | 12,732 | .00 | 0 |
| 2007-01-03 | Suvari Tricia Borga (SVP, Gen Counsel, Asst Sec) | Option Ex | 12,732 | .00 | 0 |
| 2007-01-03 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 12,732 | .00 | 0 |
| 2007-01-03 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 12,732 | .00 | 0 |
| 2007-01-03 | Lange Louis G (Chairman & CEO) | Option Ex | 30,541 | .00 | 0 |
| 2006-12-22 | Lange Louis G (Chairman & CEO) | Option Ex | 20,169 | .00 | 0 |
| 2006-12-19 | Mcneil Barbara J (Director) | Sale | 1,800 | 13.60 | 24,480 |
| 2006-12-12 | Spiegelman Daniel K (SVP, CFO) | Sale | 3,000 | 12.92 | 38,760 |
| 2006-12-05 | Mccaleb David C (SVP Commercial Operations) | Option Ex | 5,000 | .00 | 0 |
| 2006-12-05 | Suvari Tricia Borga (SVP, Gen Counsel, Asst Sec) | Option Ex | 5,000 | .00 | 0 |
| 2006-12-05 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 5,000 | .00 | 0 |
| 2006-12-05 | Blackburn Brent K (SVP, Drug Discovery & Dev) | Option Ex | 5,000 | .00 | 0 |
| 2006-12-05 | Lange Louis G (Chairman & CEO) | Option Ex | 12,000 | .00 | 0 |
| 2006-08-23 | Mcneil Barbara J (Director) | Option Ex | 1,800 | 2.50 | 4,500 |
| 2006-08-23 | Lange Louis G (Chairman & CEO) | Option Ex | 25,000 | 9.25 | 231,250 |
| 2006-05-17 | Mccaleb David C (SVP Commercial Operations) | Option Ex | 10,000 | 7.12 | 71,250 |
| 2006-05-09 | Gutshall Thomas L (Director) | Option Ex | 15,500 | 2.50 | 38,750 |
| 2006-03-07 | Mcneil Barbara J (Director) | Sale | 8,000 | 24.53 | 196,240 |
| 2006-03-07 | Mcneil Barbara J (Director) | Option Ex | 8,000 | 2.50 | 20,000 |
| 2006-01-03 | Mccaleb David C (SVP Commercial Opera) | Option Ex | 121 | .00 | 0 |
| 2006-01-03 | Suvari Tricia Borga (VP, Gen Counsel, Ass) | Option Ex | 121 | .00 | 0 |
| 2006-01-03 | Spiegelman Daniel K (SVP, CFO) | Option Ex | 121 | .00 | 0 |
| 2006-01-03 | Blackburn Brent K (SVP, Drug Discovery) | Option Ex | 121 | .00 | 0 |
| 2006-01-03 | Lange Louis G (Chairman & CEO) | Option Ex | 282 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of CVTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cv Therapeutics Inc (symbol CVTX, CIK number 921506) see the Securities and Exchange Commission (SEC) website.